Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG)

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Rowe JM. AML in 2017: advances in clinical practice. Best Pract Res Clin Haematol. 2017;30(4):283–286.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Terry CM, Shallis RM, Estey E, et al. Day 14 bone marrow examination in the management of acute myeloid leukemia. Am J Hematol. 2017;92(10):1079–1084.
   PubMed Web of Science ®Google Scholar
• Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101(1):64–70.
   PubMed Web of Science ®Google Scholar
• Gianfaldoni G, Mannelli F, Baccini M, et al. Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. Br J Haematol. 2006;134(1):54–57.
   PubMed Web of Science ®Google Scholar
• Hussein K, Jahagirdar B, Gupta P, et al. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia. Am J Hematol. 2008;83(6):446–450.
   PubMed Web of Science ®Google Scholar
• Liso V, Albano F, Pastore D, et al. Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica. 2000;85(12):1285–1290.
   PubMed Web of Science ®Google Scholar
• Norkin M, Chang M, An Q, et al. A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. Leuk Res. 2016;46:69–73.
   PubMed Web of Science ®Google Scholar
• Lemos M, Costa F, Gaspar CL, et al. Prognostic value of day 14 bone marrow biopsy (d14BM) in Acute Myeloid Leukemia (AML). Blood. 2017;30:3865.
   Google Scholar
• Ollila T, Reagan JL, Castillo JJ, et al. The role of day 14 bone marrow analysis in determining leukemia free survival and overall survival. Blood. 2015;126:4974.
   Google Scholar
• Ollila TA, Olszewski AJ, Butera JN, et al. Marrow hypocellularity, but not residual blast count or receipt of reinduction chemotherapy, is prognostic on day-14 assessment in acute myeloid leukemia patients with morphologic residual disease. Clin Lymphoma Myeloma Leuk. 2018;18(3):204–209.
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Tallman MS, Abbound CN, et al. National Comprehensive Cancer Network, NCCN Guidelines, Acute Myeloid Leukemia. Version 1.2018. Available from: www.nccn.org
   Google Scholar
• Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010;116(21):5012–5021.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Robak T, et al. Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004;18(5):989–997.
   PubMed Web of Science ®Google Scholar
• Holowiecki J, Grosicki S, Giebel S, et al. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012;30(20):2441–2448.
   PubMed Web of Science ®Google Scholar
• Wierzbowska A, Robak T, Pluta A, et al. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. Eur J Haematol. 2008;80(2):115–126.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. U.S. Department of Health and Human Services; National Institutes of Health National Cancer Institute; Published: May 28, 2009 (v4.03: June 14, 2010).
   Google Scholar
• Pluta A, Brzozowski K, Stepka K, et al. Cladribine, cytarabine and mitoxantrone as treatment intensification for patients with acute myeloid leukemia with the excess of bone marrow blasts on day 14 of the first induction. Prospective, multicenter study by the Polish Adult Leukemia Group (PALG). Abstracts of 58th Annual Meeting of the American Society of Hematology. Blood. 2016;128:Abstract 213.
   Web of Science ®Google Scholar
• Cheson BD, Bennett JM, Kopecky KJ, et al. International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2004;21(24):4642–4649.
   Web of Science ®Google Scholar
• Bucaneve G, Castagnola E, Viscoli C, et al. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer. 2007;5(2):5–12.
   Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL3 – 2009 update. Bone Marrow Transplant. 2011;46(5):709–718.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–951.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474.
   PubMed Web of Science ®Google Scholar
• Shaffer LG, McGovan-Jordan J, Schmid M, ISCN. An international system for human cytogenetic nomenclature. Basel: S. Karger; 2013.
   Google Scholar
• Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011–4020.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Gale RE, Frew ME, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–1759.
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Döhner K, Krauter J, et al., German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918.
   PubMed Web of Science ®Google Scholar
• Libura M, Pawełczyk M, Florek I, et al. CEBPA copy number variations in normal karyotype acute myeloid leukemia: possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis. Blood Cells Mol Dis. 2015;55(4):284–292.
   PubMed Web of Science ®Google Scholar
• Budziszewska BK, Pluta A, Sulek K, et al. Treatment of elderly patients with acute myeloid leukemia adjusted for performance status and presence of comorbidities: a Polish Adult Leukemia Group study. Leuk Lymphoma. 2015;56(8):2331–2338.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090–1098.
   PubMed Web of Science ®Google Scholar
• Ferrara F, Izzo T, Criscuolo C, et al. Day 15 bone marrow driven double induction in young adult patients with acute myeloid leukemia: feasibility, toxicity, and therapeutic results. Am J Hematol. 2010;85(9):687–690.
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K. Management of febril neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(5):111–118.
   PubMedGoogle Scholar
• Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249–1259.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360–3368.
   PubMed Web of Science ®Google Scholar
• Boissel N, Cayuela JM, Preudhomme C, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia. 2002;16(9):1699–1704.
   PubMed Web of Science ®Google Scholar
• Libura M, Giebel S, Piatkowska-Jakubas B, et al. Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD + normal karyotype AML patients. Blood. 2016;127(3):360–362.
   PubMed Web of Science ®Google Scholar
• Deutsch YE, Campuzano-Zuluaga G, Salzberg MP, et al. Clinical utility of morphological evaluation of day 14 bone marrow biopsies in acute myeloid leukemia patients undergoing standard induction chemotherapy: time to change practice? Blood. 2014;124:1004.
   Web of Science ®Google Scholar